8:25 am Chair’s Opening Remarks

• Bill Forrester Global Co-Lead, TPD Initiative, Novartis

Keynote Plenary Session Highlighting Key Discoveries of Bifunctional Degraders to New Targets

8:30 am Novel Small Molecule Bifunctional Degraders of SOS1 For Inhibition of Pan-KRAS Mutant Cancers

• Leah Fung CSO, Biotheryx

9:00 am PROTAC Development & Optimization to Target an Endoplasmic Reticulum Membrane Protein

• Markus Queisser Scientific Director, GSK

9:30 am Assessment of molecular glues in yeast lysate

• Henrik Jensen CSO, Fidabio
• Yehudah Pardo Senior Expert I, Data Science, Novartis

10:00 am Panel Discussion: TPD in Oncology & Beyond

• Adam Gilbert Executive Director & Head of Design & Synthesis Sciences, WRD&M, Pfizer
• Beth J. Hoffman CEO, Origami Therapeutics, Inc.
• Angela Cacace SVP of Neuroscience & Platform Biology, Arvinas
• Simon Bailey Executive VP, Drug Discovery, Plexium
• Sam Shrivastava Founder & CEO, Asha Therapeutics

Morning Networking Break & Tech Slam: Hear An Exclusive Update of the Latest Technology Available to You to Support Your Efforts in 2022 & Beyond

10:45 am Mass Photometry – Weighing Molecules with Light

• Gael Nicolas Senior Technical Sales Specialist, Refeyn

10:55 am Deep Proteomic Screening for Systematic Discovery of Degrader Targets

• Henrik Daub CSO, NEOsphere Biotechnologies GmbH

11:05 am Details to Be Revealed

12:30 pm Networking Lunch

2:30 pm Scientific Poster Session

First Look at Monovalent Degradation Strategies Taking Aim at High Value Targets

3:30 pm Progress Towards Rational, Structure-Based Design of Next-Generation Glues

• Phil Chamberlain Co-Founder, President, & CEO, Neomorph, Inc.

4:00 pm Monofunctional Degradation Activating Compounds: From New Targets to the Clinic

• Christopher G. Nasveschuk SVP, Chemistry, C4 Therapeutics

4:30 pm Gluing the Inflammasome

• Zuni Bassi Principal Scientist II, Novartis

5:00 pm Chair’s Closing Remarks & End of Conference Day Two

• Bill Forrester Global Co-Lead, TPD Initiative, Novartis